Inhibitors of N-myristoyltransferase (NMT) have been shown to inhibit retrovirus replication, notably that of the human immunodeficiency virus (HIV), where the absence of protein myristoylation inhibits viral replication. The authors have assayed 14 compounds derived from myristic acid for activity against varicella-zoster virus (human herpesvirus 3; VZV) by plaque reduction assay. Seven showed cytotoxicity and of the others, two failed to inhibit VZV replication. One of these was N-myristoylglycinaldiethylacetal (GoA), which has been reported to be active against HIV. 12-(methoxy) dodecanoic acid (13-oxamyristic acid), which has also been reported to inhibit HIV replication, was found to inhibit VZV replication but was cytotoxic at high concentrations. The greatest inhibitory effect without apparent toxicity was induced by 2-hydroxytetradecanoic acid and its enantiomers. The results of these assays provide further evidence that inhibitors of NMT have potential as antiViral agents against the many viruses with myristoylated proteins.
Myristic acid constitutes approximately 1% of cellular fatty acids in mammalian cells (Heuckeroth et aI., 1990) and is attached to the N-terminal glycine residue of proteins by the enzyme myristoyl-CoA:Protein N-myristoyltransferase (NM1). Sequence analyses of this enzyme have shown it to be highly conserved between species suggesting an important role in cell functions in both prokaryotes and eukaryotes.
Acylated proteins have been shown to playa range of important roles in both cellular and viral metabolism and it has been suggested that their increased hydrophobicity may affect processes as diverse as viral entry, enzymatic function, membrane permeability changes, intracellular transport and virion morphogenesis. In retroviruses, myristoylproteins appear to playa role in transformation (Schmidt, 1989; Harper and Gilbert, 1992) . Deletion of the N-terminal glycine of capsid proteins in Mason-Pfizer monkey virus and HIV prevents myristoylation and has been shown to result in non-viable viral particles with revertants regaining the ability to myristoylate and form viable particles (Rhee and Hunter, 1987; Gottlinger et al., 1989) . Myristoylproteins are thought also to be important in protein-protein interactions and therefore could playa role in viral assembly representing a potential target for antiviral drug development. Consequently, studies using both substituted analogues of myristic acid and inhibitors of N-myristoyltransferase as antiviral agents against human immunodeficiency virus and other retroviruses have been performed (Bryant et al., 1989 (Bryant et al., , 1991 Tashiro et al., 1989; Saermark etal.,1991; Devadas et el., 1992) .
Using plaque reduction assays, the authors studied the effects of proposed myristoylation inhibitors (provided from the Medical Research Council AIDS-directed programme) on the replication of varicella-zoster virus (human herpesvirus 3, VZV) (Harper et al., 1993) . VZV had been shown previously to produce myristoylproteins including the immunogenic major viral glycoprotein V2VgE (gp1)and the smaller Lp7 (Lipoprotein 7, molecular weight 7000; Harper and Kangro, 1990) , suggesting that it might be subject to inhibition by such compounds. However, no previous studies of such inhibitors had been centred on herpesviruses.
The compounds chosen for the study described here comprised both heteroatom-substituted analogues of myristic acid and inhibitors of N-myristoyltransferase. Oxygen-and sulfur-containing analogues of myristate included compounds which had been reported previously to inhibit HIV and Moloney leukaemia virus (Bryant et al., 1989 ) and a novel compound, 9-(butylamino)nonanoic acid, in which the heteroatom was a nitrogen. Inhibitors of NMT could be subdivided into two groups, one containing myristoylamide and myristoymethylamide, both novel compounds, and the second containing different z-substituted myristic acids. Those in the former group are weak competitive inhibitors of NMT (C.J. Blunt and RAJ. Mcllhinney, data not shown). Those in the latter group act upon conversion to their appropriate acyl-CoA and bind to NMT but cannot be transferred to the protein because of the substitution at the 2-position. This group contained compounds which had been shown previously to act in this manner and which were known to inhibit cell protein myristoylation (Paige et al., 1990) , namely 2-hydroxy and 2-bromomyristic acid. In addition, the authors synthesized 2-azidotetradecanoic acid and glycidic acid both of which have been shown to act as competitive inhibitors of NMT following their conversion to acyl-CoAs (RAJ. Mcllhinney and C.J. Blunt, data not shown).
Compounds which followed the general formula of CH3(CH2)nX(CH2)mCOOH where n + m = 11 and X = NH, o or S were synthesized using a method adapted from that used by Pascal and Ziering (1986) . All compounds with general formula CH3(CHd11CH(X)COOH were derived from 2-bromotetradecanoic acid. 2-Azidotetradecanoic acid was produced by stirring 2-bromotetradecanoic acid with sodium azide (2.5 equivalent) ans;t hexadecyl-tributylphosphonium bromide (0.1 equiva~lfnt) in water at 80°C
and the reaction was monitored by thin-layer chromato-. graphy (49% diethyl ether, 1% acetic acid in hexane). 2-Hydroxytetradecanoic acid was synthesized by stirring 2-bromotetradecanoic acid with potassium hydroxide (2 equivalent) in DMSO at 100°C for 2 h. After cooling, water was added (same volume as DMSO) and the mixture acidified with HC\. The product was extracted into diethyl ether which was subsequently removed under reduced pressure and the product was purified by crystallization. Glycidic acid, tetradecanamide and N-methyltetradecanamide were produced using methods adapted from Vogel's Textbook of Practical Organic Chemistry (Furñ ess, 1989) . GoA was synthesized as described by Shoji et al. (1988) . 2-Bromotetradecanoic acid was purchased from Aldrich Chemical Company Ltd, Gillingham (UK).
In order to facilitate a direct assay of cell growth, sub-confluent mono layers of Mewo human melanoma cells (Grose and Brunell, 1978) in 24-well plates were infected with approximately 40 PFU of cell-free varicellazoster virus 0/ZV) strain H-551 (Harper et aI., 1993) . After an adsorption period of 2 h the cells were overlaid with 75b ul of MEM supplemented with 2% fetal calf serum and 1% non-essential amino acids containing the antiviral compounds to be tested which were diluted from 80 mM stock solutions in ethanol, to give final concentrations of 0, 2, 20 or 200 fLM. The wells were overlaid with a further 750 fLl of MEM supplemented with 2% fetal calf serum, 1% non-essential amino acids and 0.3% agarose. Mock infected wells were included also as controls to test for cytotoxicity. All plates were incubated at 32°C with 5% CO 2. At 8 days post infection the monolayers were fixed in 4% formaldehyde and stained with crystal violet. Plaques
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were counted and the IC 50 values (the concentration causing a 50% reduction in plaque numbers) were calculated to the nearest integer from the resulting curve.
Toxicity of the compounds was determined by growth of subconfluent, mock-infected monolayers in the presence of 200 fLM inhibitor for 8 days prior to staining with crystal violet. Stain uptake was determined by densitometry of a central 1cm 2 region of the well and described as a percentage of the value obtained for untreated control wells. Compounds were scored as non-toxic (greater than 80% monolayer survival), slightly toxic (50-75% monolayer survival) or highly toxic (less than 10% monolayer survival).
Of the fourteen compounds tested, seven were found to be cytotoxic (Table 1) . Two out of the three compounds which had been assayed previously by other groups for antiviral activity against HIV (Table 1) were found to be toxic to Mewo cells at high concentrations. 11-(Ethylthio)undecanoic acid destroyed the cell monolayers at 200 fLM concentration and failed to induce any degree of inhibition in the authors' assay. Heuckeroth et al. (1988) studied 11-(ethylthio)undecanoic acid in cell-free systems and reported that it could act as an alternative substrate for both wheatgerm and yeast NMT after conversion to its CoA ester. No studies were carried out to determine cytotoxicity, although Heuckeroth et al. proposed that it would be taken up by cells and utilized instead of myristoyl-CoA. Bryant et al. (1989) and Devadas et al. (1992) both reported that 12-(methoxy)dodecanoic acid was not toxic to CD4+ H9 cells and could prevent the cytopathic effect caused by HIV infection of cells. The authors' assays showed the approximate IC 50 of 12-(methoxy)dodecanoic acid against VZV to be 17 fLM. This was in broad agreement with the results obtained with HIV in which Devadas et al. (1992) reported that the optimal concentration for inhibition of HIVwas 20-40 fLM. N-Myristoylglycinaldiethylacetyl (GoA) did not produce a 50% inhibition at any concentration tested. By contrast, Tashiro et al. (1989) used GoA as an inhibitor of HIVreplication and reported that 90-95% of myristoylation of the p17, p19 and other gag proteins was inhibited at concentrations of 25 fLM resulting in reduced production of mature virions.
Of the 11 novel compounds tested by the authors (Table  1) , five compounds were found to be toxic to cells. 2-Azidotetradecanoic acid destroyed the cell monolayer even at a concentration of 20 fLM. 2-Bromotetradecanoic acid, 11-(ethyloxy)undecanoic acid and glycidic acid were toxic to cells at 200 fLM concentrations but produced IC 50 values of 15, 14 and 5 fLM respectively. 2-Bromotetradecanoic acid was found by Paige et al. (1990) to be a potent inhibitor of NMT in vitro. In their assays using the T-Iymphoma cell line LSTRA no cytotoxicity was reported, but exposure to cells was limited to a maximum of 4.25 h. N-Methyltetradecanamide resulted in thinning of the monolayer and formation of large plaques indicating some cellular toxicity at high concentrations. While it produced an inhibitory effect, the observed IG so was 57 f-LM.
No IG so was obtained with 11-(ethylamino)undecanoic acid and the greatest inhibition appeared to occur at a low concentration. Tetradecanamide did not appear to cause any cellular toxicity and an IG so of 20 f-LM was obtained. However, the inhibition of VZV was not increased at higher concentrations. 9-(Butylamino)nonanoic acid was not cytotoxic, but was ineffective as an inhibitor of myristoylation since the IG so observed was 164 f-LM.
No discernable toxicity was caused by 2-hydroxytetradecanoic acid (2-hydroxymyristic acid) (Table1) but it caused a significant reduction in both the number and size of plaques. Its low IG so of 22 f-LM in these assays compares favourably with that of acyclovir (Harper et al., 1993) . These results correspond also with those found by Paige et al. (1990) when they compared the 2-bromo, 2-f1uoro and 2-hydroxy substituted derivatives of 2-hydroxytetradecanoic acid and found that 2-hydroxytetradecanoic acid had the greatest inhibitory effect on protein myristoylation in cell culture. They did not observe any inhibitory effect on palmitoylation, showing that the acylGoA synthetase enzyme was not being affected. The enantiomers of 2-HTD were also tested in this study (Table  1) and were found to cause significant reductions in plaque numbers without cellular toxicity. The IG so values obtained for the (8) and (R) enantiomers were 12 and 48 f-LM respectively.
These studies on possible inhibitors of NMT have identified a number of compounds which can cause inhibition of VZV replication without causing cellular toxicity. Virtually all the compounds tested in the authors' assays caused some inhibition of viral replication. Inhibitors of myristoylation are thought to have three possible modes of action. Compounds such as GoA are thought to block the NMT binding site (Bryant et st., 1989; Saermark et a/., 1991) preventing the uptake of myristoyl-CoA. Cells are able to survive this block since myristoylation is a stable modification and pre-formed myristoylproteins are unaffected. Analogues such as 2-hydroxytetradecanoic acid can be converted to their appropriate acyl-CoA which subsequently blocks the enzyme, while 12-(methoxy) dodecanoic acid and 11-(ethylthio)undecanoic acid can act as competitive inhibitors of myristoyl-CoA. The alternative substrates are taken up by the cells and act by altering the function and possibly the cellular distribution of myristoylproteins with varying degrees of efficiency.
Heteroatom-substituted myristate analogues may be incorporated selectively into proteins due to co-operative interactions between the enzyme 1!J!Id peptide-binding sites. Different analogues produce djtterent changes in the proteins' hydrophobicity and this may determine whether. they exhibit antiviral activity (Devadas et a/., 1992) .
As found in previous studies (Bryant et el., 1989 (Bryant et el., , 1991 Tashiro et a/., 1989; Saermark et a/., 1991) many myristoylation inhibitors are cytotoxic. In the authors' assay, seven of the 15 compounds tested were toxic to cells. This may be due to alterations in the function of the acylated proteins, for example via redistribution of membrane proteins to the cytosol or due to the production of toxic metabolites from the compounds' catabolism. Solubility was reported to be a problem by Tashiro et 8/. (1989) in GoA studies and this may be a reason why no IC so was obtained in the authors' plaque assays, despite apparent complete solubility in ethanol. This may also affect the results produced by some of the other less effective inhibitors such as 9-(butylamino)nonanoic acid.
Bryant et at. (1989) reported that the degree of inhibition of infectious virus production was dependent on the cell type. This may reflect the efficiency of cellular uptake of the compounds and the ease with which they can pass through the cellular membranes, and it may be responsible also for the variations in cytotoxic effects in different assay systems. Bryant et al. (1989) also suggested that the incorporation of myristate analogues into myristoylated cellular enzymes such as tyrosine kinases may indirectly affect HIVinfection of T-cells. By analogy, such alterations in the modifications of cellular kinases may also affect the interactions between cellular and viral proteins in VZV infection.
The results of the authors' study on 12-(methoxy)dodecanoic acid were remarkably similar to those reported previously for HIV since Devadas et al. (1992) reported an
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IC so of 20-40 fLM, compared with the finding reported here of. 17 fLM in VZV. Differences in the ICsos obtained were more striking for 11-(ethylthio)undecanoic acid and GoA. This is not surprising given the major differences in the nature and replication of the two viruses, and furthermore Bryant et at. (1989) reported differences between Moloney murine leukaemia virus and HIV, both of which are retroviruses, in their susceptibility to 12-(methoxy)dodecanoic acid.
In this paper the authors report the development of an assay system based on a melanoma cell-plaque assay and the effects of 14 compounds identified as possible inhibitors of myristoylation on VZV replication in this plaque' reduction assay. Thirteen of the compounds (all except 11-(ethylthio)undecanoic acid) resulted in some inhibition at one or more of the concentrations tested, but seven were found to be cytotoxic. 2-Hydroxytetradecanoic acid, a racemic compound, gave the most promising results against VZV and its (R) enantiomer was significantly more active than the racemic compound with neither showing significant cytotoxicy.
